Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - NEWS.MEDICAL.NET - A la Une - 14/Sep 08:17
New cancer drug shows encouraging results in Phase I/II trial
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
Articles similaires
Antibody-drug conjugate shows promise in treating ovarian and endometrial cancers
news.medical.net - 14/Sep 10:33
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from...
Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY─101 in solid tumors
pharmabiz.com - 01:13
Cytovation ASA, a clinical stage oncology company focused on the development of its first─in─class bifunctional immunotherapy CY─101 (CyPep─1)...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
financialpost.com - 10:02
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
financialpost.com - 10:02
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate...
Relay Stock Soars on Upbeat Data From Breast Cancer Study
zacks.com - 10/Sep 14:55
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for...
Relay Stock Soars on Upbeat Data From Breast Cancer Study
zacks.com - 10/Sep 14:55
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for...
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
zacks.com - 06/Sep 14:43
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin...
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
zacks.com - 06/Sep 14:43
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin...
Les derniers communiqués
-
Aucun élément